subject: this is YOUR once-in-a-lifetime chance, not ours.
What if we told you that, right here and right now, we have the power to help you live beyond 300 years? Every websites promote longevity, You might think that just means 90 years. You are so pessimistic. What if we told you that even the U.S. President has expressed support for the work we are doing for humanity? Such encouragement means a great deal to us and confirms the importance of our mission. By the way, when was the last time the U.S. President sent you a letter?
You are getting older anyways. Your money is useless, if you die. If you are serious about longevity, health, and fulfillment, or want to work with us, contact us in email: life at Alien Puppy Hawaii . com
We are the ONLY clinic in the world capable of truly extending your lifespan and improving your health. Our services are not limited to a select few global elites such as yourself. Our programs for healthy living and disease prevention are also available to the working class at a very reasonable cost. Interested? Meet with us, speak with us, visit our laboratories, and evaluate our work firsthand. You are welcome to ask us—or our clients—any questions before making your next decision. By the way, our services are available only to those who satisfy certain political requirements. Details are available on our website.
we do: life science, blockchain, Internet Security, Aerospace & Defense, Economy & Finance Research, Big Science Research.
Our existence on Earth is not just important—it’s non-negotiable.
We are the difference between relevance and collapse for your treasuries, central banks, private banks, financial elites, and national security and defense. Your stability, your prosperity, your future—none of it holds weight without the alien technologies and systems we enable. Without us, no one will care about your government, your markets, your people, or your survival. You’ll be ignored, outpaced, and left behind. We’re here because without us, you/your family/your business/your government/your people/your country/your world don’t stand a chance.
we are Alien Puppy Hawaii .
------------------------------------------------------------------
ethalo .com
Ethalo(BitBay marketplace) is the only decentralized marketplace in the world that does not rely on escrow agents. The two parties deposit against each other making fraud or theft impossible. It has over 10 years in operation with no hacks and AI moderated web markets.
bitbay .market
BitBay is one of the worlds oldest altcoins and it is the only coin with the ability to force its supply to match its demand letting users set whatever price they want for the currency by voting or algorithms. It is the perfect tool for a decentralized bank making it even harder money than Bitcoin. It also had the worlds first smart contracts and decentralized marketplace.
nighttrader .exchange
NightTrader is the first true Bitcoin based decentralized exchange which cannot be hacked as it gives users control over their accounts. It has the same speed as a centralized exchange with better security.
DO NOT reply to this email.
all those conditions listed BELOW, obviously are better off if people used our tech(Alien Puppy Hawaii TECH)
Here are several clinical trials and research efforts in Japan involving human cells—especially iPS (induced pluripotent stem cells) and related regenerative therapies. Many of these are registered as clinical studies or underway toward clinical trial status:
1. iPS-derived exosome clinical research (2025–2026)
A clinical study is underway in Japan to evaluate safety and potential efficacy of iPS cell-derived exosomes (tiny cell-derived particles) for cognitive, muscle, and immune function decline related to aging. This is an interventional randomized double-blind, placebo-controlled trial involving participants aged 50–80. JRCT
Focus: iPS cell-derived exosomes
Purpose: exploratory evaluation of effects on cognition/muscle/immune function
Phase/Type: clinical research (not specified as drug phase)
Timeline: Oct 2025 – Mar 2026 (estimated)
Subjects: 45 participants JRCT
2. Heart muscle cell transplants using iPS cells
A Kyoto-based regenerative medicine startup iHeart Japan has conducted a clinical trial using a sheet of cardiac muscle cells derived from human iPS cells in a patient with dilated cardiomyopathy. Early reports indicate the patient has been discharged and is being monitored. The Japan Times
Focus: iPS-derived cardiac muscle
Condition: dilated cardiomyopathy
Institution: Tokyo Women’s Medical University Hospital / Kyoto startup The Japan Times
3. Parkinson’s disease and neurodegeneration iPS clinical research
Japanese research groups have conducted Phase I/II clinical studies transplanting iPS-derived dopaminergic neurons into patients with Parkinson’s disease, showing safety and feasibility in early trials. National Institute of Health
Focus: PD regenerative therapy with iPS cells
Phase: I/II (early clinical trial)
Institution: Kyoto University (investigator-initiated) National Institute of Health
4. Retinal iPS/eye cell transplant research
Clinical research has been ongoing using human iPS cell-derived retinal pigment epithelium cells for wet age-related macular degeneration. Some early clinical research was initiated by institutions like Kobe City Eye Hospital. National Institute of Health
Focus: retinal cells for macular degeneration
Status: clinical research / early phase trials National Institute of Health
5. Other iPS-derived cell therapies in development
According to a regulatory summary of Japanese clinical research:
Cartilage cell transplants (knee injury)
Allogeneic iPS cardiomyocytes (dilated and ischemic heart disease)
Anti-GPC3 CAR-NK cells (ovarian cancer)
Corneal endothelial cells (bullous keratopathy)
Platelet-producing cells (thrombocytopenia)
These are clinical research trials and early stages reflecting ongoing efforts toward therapeutic application of iPS-derived cells. National Institute of Health
Background context (why Japan leads in this area)
Japan’s focus on iPS cell research stems from the pioneering work of Shinya Yamanaka, Nobel laureate for developing iPS technology, which has accelerated both basic science and clinical applications of human cells in regenerative medicine. JPMA
The Japan Regenerative Medicine Project and research networks organized by AMED (Japan Agency for Medical Research and Development) support clinical translation of iPS/ES cell therapies from lab to patients. amed.go.jp
Summary of Available Trials / Studies
Trial / Research Focus Status iPS-derived exosome trial Aging biomarker intervention Active 2025–2026 JRCT iHeart Japan heart cell transplant iPS cardiac muscle Reported trial The Japan Times Parkinson’s cell therapy Dopaminergic neurons Phase I/II National Institute of Health Retinal cell therapy Retinal pigment epithelium Early clinical research National Institute of Health Multiple iPS/ES clinical research Heart, cartilage, NK cells, cornea, etc. Ongoing research list National Institute of Health

